With the ever increasing premiums placed on novel therapies that arrive to market, it is no surprise that many countries cannot afford to approve such medicines whilst others place stringent restrictions on their use. Furthermore, most medicines are rarely successful in all those individuals for whom they are prescribed, with 60% of patients on average initially deriving benefit [1] . Likewise, in the longer term many patients lose the initial benefit gained with the trigger factors responsible for these ''flares'' largely unknown. In addition to the unpredictability of adverse events, it is no surprise that for several decades research efforts have been made to try and stratify therapies towards individuals and populations they would truly benefit [2, 3] . In the last several years, the treatments of numerous cancers have been revolutionised by molecular diagnostics. A classic example in dermatology has been the discovery of the BRAF mutation which occurs in approximately 50% of individuals with advanced malignant melanoma. Those who express this mutation will often have significant initial responses to BRAF inhibitors. The longer-term benefits still remain to be fully understood but are improved by combined therapeutic approaches [4] . (anti interleukin-13) [5] . In dermatology, the target organ skin is accessible and utilising new technologies to study RNA transcripts expressed in psoriasis at early stages of therapy may allow replication of the findings in asthma. Further, bioinformatic methods to allow integration of the large datasets produced when studying ''omics'' are now well placed to facilitate the interpretation of these data and hopefully allow successful stratification of biologic therapies [6] . capabilities to bring these less expensive biosimilar agents to market, to the current pharmaceutical companies manufacturing and marketing biologic agents [7] .
